PT - JOURNAL ARTICLE AU - Michael G. Levin AU - Derek Klarin AU - Venexia M. Walker AU - Dipender Gill AU - Julie Lynch AU - Kyung M. Lee AU - Themistocles L. Assimes AU - Pradeep Natarajan AU - Adriana M. Hung AU - Todd Edwards AU - Daniel J. Rader AU - J. Michael Gaziano AU - Neil M. Davies AU - Philip S. Tsao AU - Kyong-Mi Chang AU - Benjamin F. Voight AU - Scott M. Damrauer AU - On behalf of the VA Million Veteran Program TI - Genetic Variation in Blood Pressure and Lifetime Risk of Peripheral Artery Disease: A Mendelian Randomization Study AID - 10.1101/2020.08.23.20180240 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.23.20180240 4099 - http://medrxiv.org/content/early/2020/08/25/2020.08.23.20180240.short 4100 - http://medrxiv.org/content/early/2020/08/25/2020.08.23.20180240.full AB - Aims We aimed to estimate the effect of blood pressure and blood pressure lowering medications (via genetic proxies) on peripheral artery disease.Methods and Results GWAS summary statistics were obtained for BP (International Consortium for Blood Pressure + UK Biobank GWAS; N = up to 757,601 individuals), peripheral artery disease (PAD; VA Million Veteran Program; N = 24,009 cases, 150,983 controls), and coronary artery disease (CAD; CARDIoGRAMplusC4D 1000 Genomes; N = 60,801 cases, 123,504 controls). Genetic correlations between systolic BP (SBP), diastolic BP (DBP), pulse pressure (PP) and CAD and PAD were estimated using LD score regression. The strongest correlation was between SBP and CAD (rg = 0.36; p = 3.9 × 10−18). Causal effects were estimated by two-sample MR using a range of pleiotropy-robust methods. Increased SBP, DBP, and PP increased risk of both PAD (SBP OR 1.25 [1.19–1.31] per 10mmHg increase, p = 3 × 10−18; DBP OR 1.27 [1.17–1.39], p = 4 × 10−8; PP OR 1.51 [1.38–1.64], p = 1 × 10−20) and CAD (SBP OR 1.37 [1.29–1.45], p = 2 × 10−24; DBP OR 1.6 [1.45–1.76], p = 7 × 10−22; PP OR 1.56 [1.4–1.75], p = 1 × 10−15). The effects of SBP and DBP were greater for CAD than PAD (pdiff = 0.024 for SBP, pdiff = 4.9 × 10−4 for DBP). Increased liability to PAD increased PP (beta = 1.04 [0.62–1.45] mmHg per 1 unit increase in log-odds in liability to PAD, p = 1 × 10−6). MR was also used to estimate the effect of BP lowering through different classes of antihypertensive medications using genetic instruments containing BP-trait associated variants located within genes encoding protein targets of each medication. SBP lowering via calcium channel blocker-associated variants was protective of CAD (OR 0.38 per 10mmHg decrease in SBP; 95% CI 0.19–0.77; p = 0.007).Conclusions Higher BP is likely to cause both PAD and CAD but may have a larger effect on CAD risk. BP-lowering through calcium-channel blockers (as proxied by genetic variants) decreased risk of CAD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by US Department of Veterans Affairs grants IK2-CX001780 (Damrauer), and I01-BX003362 (Tsao/Chang). This research is based on data from the MVP, Office of Research and Development, Veterans Health Administration and was supported by award no. MVP000. This publication does not represent the views of the Department of Veterans Affairs or the United States government. This work was also supported by the National Institute of Diabetes and Digestive and Kidney Diseases R01-DK101478 (Voight), and a Linda Pechenik Montague Investigator Award (Voight). The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_12013/1, MC_UU_12013/9, MC_UU_00011/1]. NMD is supported by a Norwegian Research Council Grant number 295989.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study utilized only publicly available, de-identified summary statistics from previously published works, making it exempt from Institutional Review Board review at the University of Pennsylvania.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics for the blood pressure genome wide association study are publicly available, and may be downloaded from the NHLBI GRASP catalog (https://grasp.nhlbi.nih.gov/FullResults.aspx). MVP PAD genome wide association study summary statistics are available on dbGAP (Accession phs001672.v2.p1). Data on coronary artery disease have been contributed by CARDIoGRAMplusC4D investigators and have been downloaded from www.cardiogramplusc4d.org/data-downloads/.